Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Adverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphoma.

McCann S, Akilov OE, Geskin L.

Clin J Oncol Nurs. 2012 Oct;16(5):E164-72. Review.

PMID:
23022942
2.

Denileukin diftitox and vision loss.

Ruddle JB, Prince HM.

Leuk Lymphoma. 2007 Apr;48(4):655-6. No abstract available.

PMID:
17454621
3.

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma.

Dang NH, Pro B, Hagemeister FB, Samaniego F, Jones D, Samuels BI, Rodriguez MA, Goy A, Romaguera JE, McLaughlin P, Tong AT, Turturro F, Walker PL, Fayad L.

Br J Haematol. 2007 Feb;136(3):439-47.

PMID:
17233846
4.

Denileukin diftitox.

Figgitt DP, Lamb HM, Goa KL.

Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. Review.

PMID:
11702307
5.

Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies.

Duvic M, Geskin L, Prince HM.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):377-84. doi: 10.1016/j.clml.2013.02.020. Epub 2013 Jun 14.

PMID:
23770157
6.

Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A.

J Clin Oncol. 2010 Apr 10;28(11):1870-7. doi: 10.1200/JCO.2009.26.2386. Epub 2010 Mar 8.

7.

Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy.

Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ.

Leuk Lymphoma. 2007 Apr;48(4):808-11. No abstract available.

PMID:
17454642
8.

CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.

Talpur R, Jones DM, Alencar AJ, Apisarnthanarax N, Herne KL, Yang Y, Duvic M.

J Invest Dermatol. 2006 Mar;126(3):575-83.

PMID:
16410787
9.

Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK).

Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A.

Clin Lymphoma. 2002 Mar;2(4):222-8.

PMID:
11970761
10.
12.

Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma.

Duvic M, Martin AG, Olsen EA, Fivenson DP, Prince HM.

Leuk Lymphoma. 2013 Mar;54(3):514-9. doi: 10.3109/10428194.2012.720372. Epub 2012 Sep 3.

PMID:
22891708
13.

Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas.

Talpur R, Duvic M.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):180-5. doi: 10.1016/j.clml.2012.01.011. Epub 2012 Apr 21.

PMID:
22521504
14.

Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J.

J Clin Oncol. 2001 Jan 15;19(2):376-88.

PMID:
11208829
15.

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.

Dang NH, Hagemeister FB, Pro B, McLaughlin P, Romaguera JE, Jones D, Samuels B, Samaniego F, Younes A, Wang M, Goy A, Rodriguez MA, Walker PL, Arredondo Y, Tong AT, Fayad L.

J Clin Oncol. 2004 Oct 15;22(20):4095-102. Epub 2004 Sep 7.

16.

Optimizing denileukin diftitox (Ontak) therapy.

Duvic M, Talpur R.

Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457. Review.

PMID:
18684057
17.

Denileukin diftitox as novel targeted therapy in non-Hodgkin's lymphoma.

Walker PL, Dang NH.

Clin J Oncol Nurs. 2004 Apr;8(2):169-74. Review.

PMID:
15108419
18.

A complete and durable response to denileukin diftitox in a patient with mycosis fungoides.

Carretero-Margolis CD, Fivenson DP.

J Am Acad Dermatol. 2003 Feb;48(2):275-6.

PMID:
12582402
19.

Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.

Kuzel TM, Li S, Eklund J, Foss F, Gascoyne R, Abramson N, Schwerkoske JF, Weller E, Horning SJ.

Leuk Lymphoma. 2007 Dec;48(12):2397-402. Epub 2007 Oct 13.

PMID:
17943599
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk